Vimarsana
Biggest News Aggregation in the World

Page 2 - Former Parent News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Former Parent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Former Parent Today - Breaking & Trending Today

ParaZero Announced First Half 2023 Financial Results - Vimarsana News

ParaZero Announced First Half 2023 Financial Results

Revenues increased 137%; company completed a $7.8 Million Initial Public Offering in July 2023...

Fortrea Reports Second Quarter 2023 Results and Provides Full-Year 2023 Guidance - Vimarsana News

Fortrea Reports Second Quarter 2023 Results and Provides Full-Year 2023 Guidance

14.08.2023 - For the three months ended June 30, 2023: Revenues of $793.0 millionGAAP net income of $28.3 millionAdjusted EBITDA of $72.5 millionGAAP and adjusted earnings per share of $0.32 and $0.52, respectively Provides full-year financial outlook DURHAM, ...

ESAB Corporation Announces Second Quarter 2023 Results - Vimarsana News

ESAB Corporation Announces Second Quarter 2023 Results

Record sales and margin performance Sales up 9% with core organic growth of 6% Reported net income from continuing operations attributable to ESAB of $67 million and core adjusted EBITDA of...

FTAI Infrastructure Inc. Reports Second Quarter 2023 Results, Declares Dividend of $0.03 per Share of Common Stock - Vimarsana News

FTAI Infrastructure Inc. Reports Second Quarter 2023 Results, Declares Dividend of $0.03 per Share of Common Stock

NEW YORK, July 25, 2023 -- FTAI Infrastructure Inc. today reported financial results for the second quarter 2023. The Company’s consolidated comparative financial statements and key performance...

Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments - Vimarsana News

Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights...